These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients.
    Author: Faure P, Ramon O, Favier A, Halimi S.
    Journal: Eur J Clin Invest; 2004 Jul; 34(7):475-81. PubMed ID: 15255784.
    Abstract:
    OBJECTIVE: The role of selenium in preventing cardiovascular diseases has been largely described. Oxidative stress and the subsequent activation of nuclear factor-kappa B (NF-kappaB) have been linked to the development of vascular complications. We investigated the effects of selenium supplementation in type 2 diabetic patients on several oxidative stress parameters and NF-kappaB activity. METHODS: We enrolled 56 type 2 diabetic patients with similar glycaemic control: 21 were supplemented by selenium (960 micro g d(-1), 3 months) and 27 received a placebo, and 10 nondiabetic subjects formed the control group. To determine NF-kappaB activation, we used an electrophoretic mobility shift assay followed by a semi-quantitative determination of NF-kappaB in peripheral blood mononuclear cells. RESULTS: Selenium treatment resulted in a significant increase in plasma selenium and red-cell Se GSH px activity. It had no effect on lipid peroxidation measured by malone-dialdehyde (MDA) or on red-cell Cu/Zn SOD. NF-kappaB activity was increased by 80% in diabetic patients. In patients receiving selenium supplementation, selenium NF-kappaB activity was significantly reduced, reaching the same level as the nondiabetic control group. CONCLUSION: In type 2 diabetic patients, activation of NF-kappaB measured in peripheral blood monocytes can be reduced by selenium supplementation, confirming its importance in the prevention of cardiovascular diseases.
    [Abstract] [Full Text] [Related] [New Search]